Shin Nishio
YOU?
Author Swipe
View article: Multicenter study on the diagnostic accuracy of left ventricular hypertrophy using a fully automated echocardiographic analysis system with artificial intelligence
Multicenter study on the diagnostic accuracy of left ventricular hypertrophy using a fully automated echocardiographic analysis system with artificial intelligence Open
Background A fully automated echocardiographic analysis system utilizing artificial intelligence was provided. It enables to generate diagnostic reports based on guidelines through zero-click measurements. While the system is expected to s…
View article: Real-world safety and effectiveness of olaparib maintenance after first-relapse platinum-sensitive ovarian cancer in Japan: a multicenter historical cohort (JGOG3026)
Real-world safety and effectiveness of olaparib maintenance after first-relapse platinum-sensitive ovarian cancer in Japan: a multicenter historical cohort (JGOG3026) Open
Objective The primary objective of the study was to evaluate the safety and effectiveness of olaparib maintenance therapy in Japanese patients with platinum-sensitive first-relapsed ovarian cancer. The secondary objective was to survey the…
View article: A new hyaluronate gel spacer and injection technique for cervical cancer brachytherapy: a technical report
A new hyaluronate gel spacer and injection technique for cervical cancer brachytherapy: a technical report Open
Spacers separating the tumor from adjacent organs help improve irradiation dose parameters. We introduce a new hyaluronate gel spacer with MEIJI (ADANT®) as an alternative to the previously used Suvenyl® and its injection technique for cer…
View article: Current status of carboplatin desensitization therapy for gynecologic malignancies
Current status of carboplatin desensitization therapy for gynecologic malignancies Open
Platinum-based chemotherapies are widely used in the treatment of gynecologic malignancies and are standard treatment for initial treatment and recurrent diseases. Due to the widespread use of platinum-based regimens, the management of pla…
View article: Clinical outcomes and prognostic factors of adjuvant radiotherapy for vulvar cancer: a Japanese Gynecologic Oncology Group nationwide survey study
Clinical outcomes and prognostic factors of adjuvant radiotherapy for vulvar cancer: a Japanese Gynecologic Oncology Group nationwide survey study Open
This study aimed to analyze the clinical outcomes and prognostic factors of postoperative adjuvant radiotherapy (RT) for vulvar cancer based on a retrospective Japanese nationwide survey. Data were collected from 108 institutions for patie…
View article: Pharmacokinetic and Exposure–Response Modeling Support Body Surface Area‐Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors
Pharmacokinetic and Exposure–Response Modeling Support Body Surface Area‐Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors Open
The first‐in‐human, Phase 1 Study 101 showed antitumor activity and a tolerable safety profile of farletuzumab ecteribulin in Japanese patients with platinum‐resistant ovarian and non‐small cell lung cancer. A pharmacometric assessment eva…
View article: Efficacy of Rikkunshito on Chemotherapy-Induced Nausea and Vomiting in Patients With Uterine Corpus or Cervical Cancer Treated With Cisplatin-Based Regimen-Placebo-controlled, Double-Blind, Randomized Confirmatory Study (JORTC-KMP03)
Efficacy of Rikkunshito on Chemotherapy-Induced Nausea and Vomiting in Patients With Uterine Corpus or Cervical Cancer Treated With Cisplatin-Based Regimen-Placebo-controlled, Double-Blind, Randomized Confirmatory Study (JORTC-KMP03) Open
Background: The current standard treatment for chemotherapy-induced nausea and vomiting (CINV) with standard antiemetics is insufficient. Rikkunshito, a Japanese traditional herbal medicine, has been shown to improve cisplatin-induced anor…
View article: Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc Open
ClinicalTrials.gov Identifier: NCT03556839.
View article: Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis Open
ClinicalTrials.gov Identifier: NCT03635567.
View article: Diagnostic accuracy and prognostic factors of uterine serous carcinoma in Japanese women: a multi-center study
Diagnostic accuracy and prognostic factors of uterine serous carcinoma in Japanese women: a multi-center study Open
USC in Japanese women has characteristics different from those of endometrioid carcinoma, worse prognosis, and is difficult to diagnose preoperatively. Complete surgical staging is necessary even for early-stage disease. Additionally, new …
View article: Elevated left atrial stiffness index is a poor prognostic factor in heart failure with preserved ejection fraction undergoing transcatheter aortic valve replacement
Elevated left atrial stiffness index is a poor prognostic factor in heart failure with preserved ejection fraction undergoing transcatheter aortic valve replacement Open
Background Patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement (TAVR) present with a high prevalence of heart failure with preserved ejection fraction (HFpEF). An elevated left atrial stiffness inde…
View article: Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial Open
Efficacy and safety in the Japan subset were generally consistent with outcomes in the DUO-E ITT population. This Japanese subset analysis of DUO-E supports carboplatin/paclitaxel + durvalumab followed by durvalumab with or without olapari…
View article: Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial Open
ClinicalTrials.gov Identifier: NCT03603184.
View article: Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure Open
Importance Cervical cancer is a common and lethal cancer worldwide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (or transforming…
View article: Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study
Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study Open
Background We previously demonstrated the applicability of the concept of “platinum sensitivity” in recurrent endometrial cancer. Although immune checkpoint inhibitors have been widely incorporated into endometrial cancer treatment, the de…
View article: Upregulated Nuclear Y-box Binding Protein-1 Expression is Closely Associated with Mammalian Target of Rapamycin Expression in Endometrial Cancer
Upregulated Nuclear Y-box Binding Protein-1 Expression is Closely Associated with Mammalian Target of Rapamycin Expression in Endometrial Cancer Open
Enhanced oncogenic Y-box binding protein-1 (YB-1) expression, associated with the aberrant expression of genes involved in cell proliferation, survival, and drug resistance, can predict prognostic outcomes in patients with various malignan…
View article: High Expression of NDRG1 is a Poor Prognostic Factor in Patients with Endometrial Endometrioid Carcinoma with Long-Term Observation
High Expression of NDRG1 is a Poor Prognostic Factor in Patients with Endometrial Endometrioid Carcinoma with Long-Term Observation Open
N-myc downstream regulated gene-1 (NDRG1) has attracted much attention as a protein associated with angiogenesis. This study investigated the associations of NDRG1 expression, determined by immunohistochemical analysis, with other clinicop…
View article: A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study
A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study Open
Introduction Hypersensitivity reactions (HSRs) to chemotherapy are serious adverse events associated with cancer drug therapy and can occur with any antitumor drug. This study investigated the safety and efficacy of carboplatin desensitiza…
View article: Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study
Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study Open
This study evaluated the long-term safety and efficacy of niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer.
View article: PR037/#494 Pre-treatment systemic inflammatory markers predict survival in endometrial cancer: a Japanese gynaecologic oncology group (JGOG) 2043 exploratory data analysis
PR037/#494 Pre-treatment systemic inflammatory markers predict survival in endometrial cancer: a Japanese gynaecologic oncology group (JGOG) 2043 exploratory data analysis Open
Introduction Inflammation predisposes patients to tumorigenesis by damaging DNA, stimulating angiogenesis, and potentiating pro-proliferative and anti-apoptotic processes. This study investigated whether pre-treatment systemic inflammatory…
View article: Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial Open
PURPOSE Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)–deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibito…